Dishman Carbogen Amcis Ltd's Q3FY25 Quarter Results
- 13 Feb 2025
Result Summary
- Dishman Carbogen Amcis Ltd reported a 13.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 4.7%.
- Its expenses for the quarter were down by 11.7% QoQ and 8.4% YoY.
- The net profit decreased 86.0% QoQ and decreased 107.8% YoY.
- The earnings per share (EPS) of Dishman Carbogen Amcis Ltd stood at 0.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 687.97 | 795.69 | 657.14 | -13.5% | 4.7% |
Total Expenses | 662.96 | 750.61 | 723.43 | -11.7% | -8.4% |
Profit Before Tax | 27.05 | 42.12 | -66.29 | -35.8% | -140.8% |
Tax | 22.42 | 9.03 | -6.66 | 148.3% | -436.6% |
Profit After Tax | 4.63 | 33.09 | -59.63 | -86.0% | -107.8% |
Earnings Per Share | 0.30 | 2.10 | -3.80 | -85.7% | -107.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dishman Carbogen Amcis Ltd is a company known for its role in the pharmaceutical industry. It primarily engages in the development, manufacture, and supply of active pharmaceutical ingredients (APIs) and intermediates. The company serves a global clientele, including pharmaceutical and biotechnology firms, by providing a range of services from drug discovery to commercial manufacturing. Dishman Carbogen Amcis Ltd operates within a competitive and highly regulated industry, where innovation and compliance are critical to success. Any recent major developments specific to the company are not available in the provided data.
Revenue
In Q3FY25, Dishman Carbogen Amcis Ltd reported a total income of ₹687.97 crores, reflecting a decline from ₹795.69 crores in the previous quarter (Q2FY25). This quarter-over-quarter (QoQ) decrease of 13.5% contrasts with a year-over-year (YoY) increase of 4.7% compared to Q3FY24, when the total income was ₹657.14 crores. The fluctuation in revenue highlights the variability in the company's financial performance within different timeframes. It is essential to consider these numbers within the broader context of the company's operational and market conditions.
Profitability
The company's profitability metrics for Q3FY25 show a significant reduction. Profit Before Tax (PBT) was ₹27.05 crores, down 35.8% from ₹42.12 crores in Q2FY25. The year-over-year comparison exhibits a notable turnaround from a loss of ₹66.29 crores in Q3FY24. Tax expenses in Q3FY25 surged to ₹22.42 crores, a substantial increase from ₹9.03 crores in the previous quarter. This rise in tax expenditure influenced the Profit After Tax (PAT), which decreased to ₹4.63 crores from ₹33.09 crores in Q2FY25, marking an 86.0% decline QoQ. Compared to Q3FY24, the PAT reflects a substantial recovery from a loss of ₹59.63 crores, underscoring the volatility in profitability over the past year.
Operating Metrics
The Earnings Per Share (EPS) for Q3FY25 stood at ₹0.30, a significant drop from ₹2.10 reported in the previous quarter, indicating an 85.7% decline QoQ. This figure also marks a recovery from a negative EPS of ₹3.80 in Q3FY24. The overall expenses for the quarter were ₹662.96 crores, which represents an 11.7% decrease from Q2FY25's ₹750.61 crores. Compared to Q3FY24, when expenses were ₹723.43 crores, there is an 8.4% reduction YoY. The trends in these operating metrics provide insight into the company's cost management and earnings performance over time.
